Product Details
Product Name:
Thymectacin |
CAS No.:
232925-18-7 |
Purity:
99.82% |
Supply Ability:
10g |
Release date:
2024/11/18 |
Product Introduction
Bioactivity
名稱(chēng) | Thymectacin |
描述 | Thymectacin (NB 1011) is a selective thymidine synthase (TS) inhibitor with anticancer activity for the study of colon cancer and solid tumors. |
體外活性 | The main clinical candidate, Thymectacin, showed only moderate activity in vitro, with EC50 values ranging from 79-245 μM in our assay. However, relatively minor structural adjustments resulted in a significant increase in potency.MDA-MB 231 EC50=79 μM, HT 115 EC50=245 μM, and PC-3 EC50=155 μM. [1] |
存儲(chǔ)條件 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 80 mg/mL(139.30 mM), Sonication is recommended.
|
關(guān)鍵字 | Thymectacin |
相關(guān)產(chǎn)品 | Rifampicin | 5-Fluorouracil | Procaine | Ribavirin | Guanidine hydrochloride | Trimethoprim | N-Nitrosodiethylamine | Azelaic acid | Acyclovir | Thymidine | Temozolomide | Folic acid |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1315323-00-2
$32.00 / 5mg
-
CAS:435-97-2
$30.00 / 10mg
-
CAS:219793-45-0
$30.00 / 2mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |